Rizatriptan Benzoate Tablet
Product Images NDC 71205-644

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71205-644). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
Figure 1 displays estimated probabilities of obtaining headache relief (no or mild pain) following treatment with Rizatriptan Benzoate or placebo in four outpatient studies (Studies 1, 2, 3, and 4). The averages shown on the Kaplan-Meier plot are based on pooled data from these placebo-controlled trials. Patients not responding prior to two hours or receiving additional treatment are censored at two hours.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
The text describes a Kaplan-Meier plot of estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled Studies 1, 2, 3, and 4. The plot shows the percentage of patients taking a second dose at different time intervals up to 24 hours post-dose. Patients who had no response to the initial dose and those who had a headache response at 2 hours are included in the plot. The plot is based on data obtained from 4 placebo-controlled outpatient clinical trials. The text also indicates that remedication was not allowed within 2 hours post-dose and patients not using additional treatments were censored at 24 hours.*
FDA Label Image

Figure3 (Rizatriptan Fig3)

Figure3 (Rizatriptan Fig3)
This appears to be a partial data table or graph. It shows the percentage (with a 95% confidence interval) at different time intervals (0, 2, 4, 6, 8, 24 hours) after taking Rizatriptan Benzoate orally disintegrating tablets compared to a placebo. However, without further context or information, it is not possible to provide a more specific description or interpretation of the data.*
FDA Label Image

71205-644-12 (Rizatriptan Fig5)

71205-644-12 (Rizatriptan Fig5)
This is the description of a prescription drug named Rizatriptan Benzoate 10mg in the form of 12 tablets. It contains instructions on how to store it and each tablet contains 14.53 mg of rizatriptan benzoate USP equivalent to rizatriptan 10 mg. The tablets are pale pink-colored, circular, flat beveled-edge uncoated tablets debossed with ‘rizatriptan’ on one side and ‘14’ on the other side. The drug is labeled by Proficient Rx LP, Thousand Oaks, CA, and manufactured by Aurobindo Pharma Limited Hyderabad-500 038, India. The lot number of the drug is 00000, and the expiration date is 00/00/00.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.